Latest news ...
Some of our recent news articles.
Sanofi to acquire Kymab for up to $1.45bn
PARIS and CAMBRIDGE, UK – January 11, 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.
Read the full story »
Sanofi to create massive standalone API producer by melding 6 sites in Europe; IPO to come
Paris - February 24, 2020 – Sanofi plans to create a major leading European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential molecules responsible for the beneficial effects used in the composition of any drug. The project consists of creating a standalone company which would combine Sanofi’s API commercial and development activities with six of its European API production sites : Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France).
Read the full story »
Sanofi confident for 2019 despite Q3 sales slip
Sales at the drugmaker’s vaccines unit down 9.8% over delay in WHO’s choice of flu inoculation
Read the full story »
Sanofi vows to limit 2017 price hikes to 5.4% as part of new 'holistic' policy
Sanofi may be late to the pricing-pledge party, but it’s come up with some benchmarks that could have other drugmakers defending their own. Rather than limiting price hikes to less than 10%, the French drugmaker promises to keep any price increases at or below an official health inflation measure that’s projected to hit 5.4% in 2017.
Read the full story »
Sanofi in talks to acquire biotech Actelion as J&J bows out
Swiss drugmaker Roche also touted as possible buyer for Europe’s largest biotech firm
Read the full story »
Sanofi deepens cancer drive with $1.2 billion of deals, Innate jumps
Sanofi boosted its presence in cancer research on Monday by signing two deals with biotech companies worth up to $1.2 billion, as the French drugmaker plays catch-up with rivals in the hot research field.
Read the full story »
Sanofi sees strong profit growth from 2018
Sanofi said on Friday investment in products to compensate for declining diabetes sales and cost cuts would prevent significant profit growth in the next two years.
Earnings per share will, however, grow faster than sales at constant exchange rates from 2018, by which time it plans to have taken out some €1.5 billion of costs, the French drugmaker said. Sanofi also said ahead of a presentation of its five-year strategic plan to investors in Paris it would raise annual research and development spending to €6 billion at constant exchange rates by 2020.
Read the full story »
Sanofi names Olivier Brandicourt as chief executive
French drugmaker Sanofi has named Olivier Brandicourt, a Paris-educated doctor and head of Bayer’s healthcare arm, as its chief executive officer.
Mr Brandicourt had been widely tipped to become Sanofi’s new boss, a position that opened when Chris Viehbacher was suddenly sacked last year.
The 59-year-old Frenchman, who researched tropical and infectious diseases before joining the corporate pharmaceutical world, will take over as chief executive on April 2
Read the full story »
